Anders Fugelli, head of business development at Lytix Biopharma provided an update on the Phase I study of Oncopore (LTX-315) for the treatment of solid tumours.
Set up to include patients at two main centres The Norwegian Radium Hospital and the Karolinska University Hospital in Stockholm, Sweden, the study is expected to initially establish a safe and tolerated dose of LTX-315 when given to solid tumours amenable to injection.
Lytix Biopharma intends to develop Oncopore to a clinical Proof-of-Concept stage whilst seeking pharma/biotech partners to support later-stage clinical development and commercialisation.
Lytix Biopharma said that the study received regulatory and ethical approvals at the end of last year and is currently actively including patients. Up to 40 patients with transdermally accessible solid tumours are expected to be included. The study is expected to investigate the primary tumour necrotic event after local injection as well as the subsequent triggering of an anti-tumour immune response such as observed in animal models.